After showing that Pfizer (NYSE:PFE) has halted its cooperation to develop giroctocogene fitelparvovec, an experimental gene therapy for hemophilia A in adults, Sangamo Therapeutics (NASDAQ:SGMO) shares fell over 50% on Tuesday. Sangamo will recover complete development and commercialization rights for the medicine after the decision. Sangamo CEO Sandy Macrae pointed out that Pfizer had revealed positive findings from a Phase 3 study in July, implying the medication is "well-positioned for regulatory filings and potential commercialization." Macrae expressed dissatisfaction and said the business intends to "explore all options to advance the program," including looking at a new collaborative partner.
Sangamo shares remain more than 90% higher year-to-date despite the massive drop; Pfizer shares went somewhat higher during the session. Moreover, Sangamo stock is up a whopping 191% in the past six months alone, leaving broader market gains in the dust. However, the recent development is likely to have a long-term impact on the stock's price as we move into the new year.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。